An interventional study of Double Antibiotic paste and Calcium Hydroxide Paste - Non-Setting in Biological Markers, sponsored by Cairo University. Status unknown. Open to participants aged 20 Years to 45 Years. Per ClinicalTrials.gov, last updated 2020-10-19.
Sponsored by Cairo University · Not applicable, Interventional, and Treatment
The aim of the present study is to evaluate the effect of double antibiotic paste when compared to Ca (OH)2, in terms of RANKL and OPG levels in chronic periapical lesions and correlate the results with periapical bone healing findings after a follow up period of one year.
Apical periodontitis is an inflammatory disease that occurs as a consequence of the bacterial infection of dental pulp tissue. It represents an inflammatory/immune pathogenesis affecting the periapical tissue including the surrounding bone. This periapical process is primarily initiated by bacterial infection in the necrotic pulp. Its persistence, progression to chronic lesions and destruction of bone structures are a consequence of the inability of host-defense mechanisms to eradicate infection. Periapical lesions are characterized histologically by fibrous and granulated tissue, infiltrated by different inflammatory cells.
Up to now the diagnosis and follow-up of asymptomatic apical periodontitis AAP is based on a clinical radiographic evaluation, however, this reflects the accumulated damage from previous episodes of periodontal tissue destruction. Moreover, the clinical presentation does not reflect the underlying inflammatory response. In accordance, differences in disease severity involve qualitatively and quantitatively different inflammatory responses. Nowadays, the challenge focuses on the necessity of designing innovative non-invasive chair-side point-of-care assessment methods, accounting for the biological profile as a complement to the existing clinical-radiographic assessment to contribute to the early evaluation of treatment outcome.
Rationale for conducting the research:
When dental pulp is infected or inflamed, various inflammatory mediators, including cytokines, chemokines, and neuropeptides, are released by innate and adaptive immune cells. During the development of pulp inflammation, inflammatory mediators result in the formation of apical osteolytic lesions. Bone loss is mainly caused by activated osteoclasts. Various cytokines such as interleukin (IL)-1, IL-11, IL-17, and tumor necrosis factor alpha (TNF-a) stimulate osteoclast progenitor cell differentiation and activation by the osteoprotegerin (OPG)/nuclear factor kappa B ligand (RANKL)/nuclear factor kappa B (RANK) complex.
The molecular mechanisms underlying bone resorption are regulated by the interaction between RANKL and OPG.The interaction between RANKL and RANK is necessary for the differentiation and activation of osteoclasts. This is modulated by OPG, which, in turn, suppresses osteoclast differentiation by preventing the interaction between RANKL and RANK.The production of OPG and RANKL by different cell types is regulated by local and systemic stimuli, including bacterial products, hormones, and inflammatory mediators.Changes in the balance of the mediators determine the progression and severity of bone diseases such as those found in periapical and periodontal lesions.
It has been reported that antibiotics regulate the immune response through modulation of cytokines production. Therefore, the level of cytokines, RANKL, and OPG can also be affected by antibiotics. In the infected root canal system, virulence products, antigens, and microbial cells are the main causes of apical periodontitis. Microorganisms in the root canal system adhere to root canal walls, isthmuses, ledges and commonly formed biofilm communities.The application of antimicrobial intra-canal medication is recommended to eliminate bacteria that could not be removed from the root canal system after instrumentation and irrigation of the root canals.
Calcium hydroxide (Ca (OH)2) is generally preferred in endodontics as an intracanal medicament because of its antimicrobial and biological effects. Because of its solubility, Ca (OH)2 releases calcium and hydroxyl ions slowly providing an alkaline environment in the periapical region.
There has been only a single in vivo study performed to evaluate the effect of Ca (OH)2 combined with ciprofloxacin or ibuprofen on the release of RANKL/OPG in periapical lesions. The aim of the present study is to evaluate the effect of double antibiotic paste when compared to Ca (OH)2, in terms of RANKL and OPG levels in chronic periapical lesions and correlate the results with periapical bone healing findings after a follow up period of one year.
Cairo University is the lead sponsor of 4,780 studies on the registry; 1,427 are open to participants now.
Of its 36 completed or terminated interventional studies of FDA-regulated products, 5 (14%) have results posted.
Counted across the registry records on this site, refreshed daily.
Single canaled teeth:
Exclusion Criteria:
500 mg Metronidazole tablet+ 500 mg Ciprofloxacin tablet crushed into powder and mixed together with salline to form a creamy mix to be placed inside the root canal for 1 week.
Drug: Double Antibiotic paste
Calcium hydroxide paste (Metapaste) placed inside the root canal for 1 week
Drug: Calcium Hydroxide Paste - Non-Setting
Metronidazole and Ciprofloxacin
Also known as: Bimix
Calcium hydroxide paste to be delivered inside the canal as an intra-canal medication
Also known as: Metapaste
Percentage change of RANKL/OPG levels
RANKL/OPG levels will be measured post-instrumentation and 1 week postoperatively, using Absorbance using ELISA test, to calculate the percentage change of RANKL/OPG levels
Time frame: measured Immediately post-instrumentation and after one week
Periapical healing
Periapical healing will be evaluated using CBCT (The lesion size is given a score according to the CBCT periapical index proposed by Estrela
Time frame: CBCT scans will be done preoperatively and 6 and 12 months postoperatively
No study locations are listed for this record.
This study is status unknown, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Cairo University